Ligilactobacillus salivarius CNCM I-4866, a potential probiotic candidate, shows anti-inflammatory properties in vitro and in vivo
Frontiers in Microbiology · 29.11.2023 · 14
DOI: 10.3389/fmicb.2023.1270974 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Microbiology, online erschienen am 29.11.2023. Verfasst von Celia Carbonne und 6 weiteren Autor:innen. Beteiligte Einrichtung: Micalis Institute, AgroParisTech, INRAE, Université Paris-Saclay, Jouy-en-Josas, France. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
The aim of this work was to characterize a new strain of Ligilactobacillus salivarius (CNCM I-4866) (CNCM I-4866) to address its potential as probiotic with a special focus on intestinal inflammation. Potential anti-inflammatory abilities of this strain were evaluated through in vivo and in vitro experiments.
Methods
Firstly, the strain was tested in a murine acute inflammation colitis model induced by DNBS. In vitro characterization was then performed with diverse tests: modulation capability of intestinal permeability; study of the impact on immunity profile through cytokines dosage; capacity to inhibit pathogens and adhere to intestinal cells lines. Production of metabolites, antibiotic resistance and survival to gastro-intestinal tract conditions were also tested.
Results
In vitro assay has shown a reduction of colonic damage and markers of inflammation after treatment with CNCM I-4866. Transcriptomic analysis performed on colons showed the capacity of the strain to down-regulate pro-inflammatory cytokines. L. salivarius CNCM I-4866 exerted anti-inflammatory profile by reducing IL-8 production by TNF-α stimulated cell and modulated cytokines profile on peripheral blood mononuclear cells (PBMC). It protected intestinal integrity by increasing trans-epithelial electrical resistance (TEER) on Caco-2 TNF-α inflamed cells. Additionally, L. salivarius CNCM I-4866 displayed inhibition capacity on several intestinal pathogens and adhered to eukaryotic cells. Regarding safety and technical concerns, CNCM I-4866 was highly resistant to 0.3% of bile salts and produced mainly L-lactate. Finally, strain genomic characterization allowed us to confirm safety aspect of our strain, with no antibiotic gene resistance found.
Discussion
Taken together, these results indicate that L. salivarius CNCM I-4866 could be a good probiotic candidate for intestinal inflammation, especially with its steady anti-inflammatory profile.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Micalis Institute, AgroParisTech, INRAE, Université Paris-Saclay, Jouy-en-Josas, France.
Zitieren
APA
Carbonne, C., Chadi, S., Kropp, C., Molimard, L., Chain, F., Langella, P., & Martin, R. (2023). Ligilactobacillus salivarius CNCM I-4866, a potential probiotic candidate, shows anti-inflammatory properties in vitro and in vivo. Frontiers in Microbiology, 14. https://doi.org/10.3389/fmicb.2023.1270974
Vancouver
Carbonne C, Chadi S, Kropp C, Molimard L, Chain F, Langella P, et al. Ligilactobacillus salivarius CNCM I-4866, a potential probiotic candidate, shows anti-inflammatory properties in vitro and in vivo. Frontiers in Microbiology. 2023;14. doi:10.3389/fmicb.2023.1270974
BibTeX
@article{Carbonne2023,
author = {Carbonne, Celia and Chadi, Sead and Kropp, Camille and Molimard, Lise and Chain, Florian and Langella, Philippe and Martin, Rebeca},
title = {Ligilactobacillus salivarius CNCM I-4866, a potential probiotic candidate, shows anti-inflammatory properties in vitro and in vivo},
journal = {Frontiers in Microbiology},
year = {2023},
volume = {14},
doi = {10.3389/fmicb.2023.1270974}
}
EUVIMED